Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Bhargava S, Bamaca-Colbert MY, Witherspoon DP, Pomerantz EM, Robins RW. Examining socio-cultural and neighborhood factors associated with trajectories of Mexican-origin mothers' education-related involvement. J Youth Adolescence. 2017 Aug;46(8):1789-804. doi: 10.1007/s10964-016-0628-6
Bhargava S, Witherspoon DP. Parental involvement across middle and high school: exploring contributions of individual and neighborhood characteristics. J Youth Adolescence. 2015 Sep 1;44(9):1702-19. doi: 10.1007/s10964-015-0334-9
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.